Dianthus Therapeutics (NASDAQ:DNTH) Director Sells $844,827.50 in Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Director Anne Mcgeorge sold 7,750 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $109.01, for a total value of $844,827.50. Following the sale, the director owned 1,250 shares in the company, valued at approximately $136,262.50. This represents a 86.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Dianthus Therapeutics Price Performance

Shares of DNTH stock opened at $109.60 on Friday. The stock has a market cap of $5.99 billion, a P/E ratio of -26.41 and a beta of 1.22. Dianthus Therapeutics, Inc. has a one year low of $19.84 and a one year high of $114.55. The stock has a fifty day moving average price of $96.76 and a 200 day moving average price of $82.61.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. The business had revenue of $0.76 million during the quarter, compared to the consensus estimate of $0.30 million. Equities research analysts anticipate that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current year.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Truist Financial upped their target price on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. HC Wainwright lifted their price objective on Dianthus Therapeutics from $130.00 to $158.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Wall Street Zen upgraded Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Friday, July 17th. Finally, TD Cowen restated a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $124.27.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of Dianthus Therapeutics by 24.7% during the fourth quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock worth $84,417,000 after buying an additional 406,254 shares during the last quarter. UBS Group AG boosted its stake in Dianthus Therapeutics by 342.6% in the fourth quarter. UBS Group AG now owns 606,620 shares of the company’s stock valued at $24,999,000 after acquiring an additional 469,547 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in Dianthus Therapeutics by 1,275.3% in the fourth quarter. BNP Paribas Financial Markets now owns 475,749 shares of the company’s stock valued at $19,606,000 after acquiring an additional 441,156 shares during the last quarter. SummitTX Capital L.P. grew its holdings in Dianthus Therapeutics by 13.8% during the 1st quarter. SummitTX Capital L.P. now owns 100,044 shares of the company’s stock worth $8,396,000 after acquiring an additional 12,118 shares during the period. Finally, California State Teachers Retirement System raised its position in shares of Dianthus Therapeutics by 155.5% during the 1st quarter. California State Teachers Retirement System now owns 40,584 shares of the company’s stock valued at $3,406,000 after acquiring an additional 24,697 shares during the last quarter. Institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.